Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (original) A composition comprising:

(i) a modified polypeptide comprising:

(a) a polypeptide derived from the extracellular domain of CD46; and

(b) a component capable of binding to a cell surface molecule; and

(ii) an adenovirus of the subtype B.

2. (original) The composition of claim 1, wherein said adenovirus is Adenovirus 3.

3. (currently amended) The composition ~~of any~~ of claims 1 ~~to 2~~, with the proviso that the component (b) of the modified polypeptide is neither a polypeptide derived from CD55 nor an Fc receptor.

4. (currently amended) The composition ~~of any~~ of claims 1 ~~to 3~~, wherein the polypeptide (a) of the modified peptide does not comprise the wildtype STP-A region of CD46.

5. (currently amended) The composition ~~of any~~ of claims 1 ~~to 4~~, wherein the polypeptide (a) of the modified polypeptide comprises at least all four SCR-regions of CD46, and preferably also comprises the regions STP-B and STP-C of CD46.

6. (currently amended) The composition ~~of any~~ of claims 1 ~~to 5~~, wherein the polypeptide (a) of the modified polypeptide is encoded by a nucleic acid comprising:

(i) a nucleic acid sequence as defined in the SEQ IDs No. 12, 14 or 16;

(ii) a nucleic acid sequence which hybridizes to the nucleic acid sequence as defined in (i) under stringent conditions;

(iii) a nucleic acid sequence which is degenerate as a result of the genetic code to the nucleic acid sequence as defined in (i) and (ii) and which encodes a polypeptide having essentially the same binding activity as the extracellular domain of CD46; or

(iv) a nucleic acid sequence having a sequence identity of at least 70% with the nucleic acid sequence as defined in (i), or a fragment thereof, and which encodes a polypeptide having essentially the same binding activity as the extracellular domain of CD46.

7. (original) The composition of claim 1, wherein the polypeptide (a) of the modified polypeptide is defined as in the amino acid sequence according to SEQ IDs No. 13, 15 or 17.

8. (currently amended) The composition ~~of any~~ of claims 1 ~~to 7~~, wherein the component (b) of the modified polypeptide is selected from the group consisting of a

small organic molecule, a peptide, and a polypeptide, wherein preferably component (b) of the modified polypeptide is not a polypeptide derived from a polypeptide of the complement pathway.

9. (cancelled)

10. (original) The composition of claim 8, wherein the small organic molecule is selected from the group consisting of a non-proteinaceous hormone, a neuro-transmitter and a synthetic molecule capable of binding to a surface receptor.

11. (original) The composition of claim 8, wherein the component (b) of the modified polypeptide is capable of specific binding to a surface receptor with a dissociation constant of lower than 1μM.

12. (currently amended) The composition ~~of any~~ of claims 1 ~~to 11~~, wherein the component (b) of the modified polypeptide is capable of binding a molecule selected from the group consisting of a cell type-specific cell surface molecule, a disorder-specific cell surface molecule, a cell-surface receptor, a cell-adhesion molecule and a sugar moiety located on one of the aforementioned molecules, in particular wherein the component (b) is capable of binding a molecule selected from the group consisting of a leukocyte antigen, a receptor tyrosine kinase, a receptor of the TNF receptor family, a cytokine receptor, a G-protein-coupled-receptor, a receptor tyrosine phosphatase, a

chemokine receptor, a scavenger receptor, a Fc-receptor, a tetraspannin, a member of the Ig-superfamily and a lectin.

13. (currently amended) The composition of claim 12, wherein the component (b) of the modified polypeptide is an ~~anti-body~~ antibody or an antibody fragment, wherein preferably said antibody fragment is selected from the group consisting of an scFab, Fab, $F(ab')_2$, diabodies, and an scFv.

14. (cancelled)

15. (currently amended) The composition of claim 8, wherein the polypeptide of (b) of the modified polypeptide is selected from the group consisting of a ligand of cell type-specific cell surface molecule, a ligand of a disorder-specific cell surface molecule, a ligand of a cell-surface receptor, a ligand of a cell-adhesion molecule and a ligand of a sugar moiety located on one of the aforementioned molecules, in particular wherein component (b) is selected from the group consisting of a ligand of a leukocyte antigen, a ligand of a receptor tyrosine kinase, a ligand of a ~~recep-tor~~ receptor of the TNF receptor family, a ligand of a cytokine receptor, a ligand of a G-protein-coupled-receptor, a ligand of a receptor tyrosine phosphatase, a ligand of a chemokine receptor, a ligand of a scavenger receptor, a ligand of a Fc-receptor, a ligand of a tetraspannin, a ligand of a member of the Ig-superfamily and a ligand of a lectin.

16. (currently amended) The composition ~~of any~~ of claims 1 ~~to 15~~, wherein the polypeptide of (a) and the component (b) of the modified polypeptide are linked to each other by a covalent linkage, preferably chemical crosslinking or genetic fusion.

17. (currently amended) The composition ~~of any~~ of claims 1 ~~to 16~~, wherein the polypeptide of (a) and the component (b) of the modified polypeptide are crosslinked via a spacer, wherein the spacer is selected from the group consisting of heterobifunctional cross-linkers, flexible amino acid linkers, like the hinge regions of Immunoglobulins, glycine serine linkers and glycine linkers, homobifunctional cross-linkers and stable ligand-receptor pairs, like for example the biotin-streptavidin system.

18. (currently amended) The composition ~~of any~~ of claims 1 ~~to 17~~, wherein the modified polypeptide is defined as in the amino acid sequence according to SEQ IDs No. 19 or 21.

19. (currently amended) A composition according to ~~any of~~ claims 1 ~~to 18~~ for use in medicine.

20. (currently amended) A pharmaceutical composition comprising a composition according to ~~one of~~ claims 1 ~~to 18~~ and a pharmaceutically acceptable carrier.

21. (currently amended) The pharmaceutical composition of claim ~~20~~ 18, wherein the adenovirus has been genetically engineered by introducing a therapeutically active gene construct comprising a therapeutically active gene operably linked to at least one regulatory sequence for expression of the therapeutically active gene.

22. (cancelled)

23. (cancelled)

24. (currently amended) The pharmaceutical composition of claim ~~23~~ 21, wherein the therapeutically active gene is a tumor supressor gene, for example selected from the group consisting of p53, Retinoblastoma, NF2, BRCA1, BRCA2, MSH2, MSH6, MLH1, CDKN2, Apaf1, DPC4, PKD1, HPC1 and VHL.

25. - 51. (cancelled)